DEPLOY

Buying guide

Evie Ring (and EvieMED) vs Withings ScanWatch in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Attribute
No image on file
Evie Ring (and EvieMED)View full model page →
Glucose monitoring, glaucoma visual field virtual reality, and the new Withings BodyScan 2
Withings ScanWatchView full model page →
ManufacturerMovano HealthWithings
Form factorbiometricbiometric
Maturitycommercialcommercial
Autonomy——
Availabilitypausedpausedshipping-nowshipping
PriceNot announced$349-$600 (actual sale price)
Capability claims——
Brain——
Verified deployments1United States1Global
Privacy practices—4biometric-storage, data-sale, data-deletion-control, data-retention
Sources on file810

Editorial summaries

Evie Ring (and EvieMED)

Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued. Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma. DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).

Withings ScanWatch

The Withings ScanWatch (the ScanWatch 2 at about $349 and the ScanWatch Nova, including the Nova Brilliant at about $600, November 2024; from Withings, founded 2008 in France and independent since buying itself back from Nokia in 2018) is the hybrid-analog entry of the biometric cohort: a conventional analog watch dial paired with medical sensors (optical PPG, electrical ECG, SpO2, and TempTech24/7 continuous temperature) and about 30-day battery. Its cleared features include ECG (for AFib, sinus rhythm, and high heart rate, cleared 2021, with an OTC ECG clearance in 2025), SpO2 with breathing-disturbance detection, and temperature trends, with an optional Withings+ subscription (~$9.95/month). It carries substantial peer-reviewed cardiologist validation for the size of the company. Cap-flag: as a French maker it is cleared in both the EU and the US, with different specific indications by region.

Common questions

What is the difference between Evie Ring (and EvieMED) and Withings ScanWatch?
Evie Ring (and EvieMED) and Withings ScanWatch are both biometric robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
Which has more verified deployments, Evie Ring (and EvieMED) or Withings ScanWatch?
Evie Ring (and EvieMED) and Withings ScanWatch each have 1 verified deployment on the DEPLOY registry (confirmed at named sites with primary sources).

Recent coverage

Related comparisons

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructionsDownload for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots